Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Shares Outstanding (Diluted Average) (2021 - 2025)

Precision Biosciences (DTIL) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $10.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 62.77% to $10.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.7 million, a 62.77% increase, with the full-year FY2024 number at $6.9 million, up 79.2% from a year prior.
  • Shares Outstanding (Diluted Average) was $10.7 million for Q3 2025 at Precision Biosciences, down from $11.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $110.8 million in Q3 2022 to a low of $2.9 million in Q4 2022.
  • A 5-year average of $26.4 million and a median of $6.9 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 91.06% in 2022, then tumbled 96.54% in 2023.
  • Precision Biosciences' Shares Outstanding (Diluted Average) stood at $58.7 million in 2021, then tumbled by 95.01% to $2.9 million in 2022, then soared by 31.11% to $3.8 million in 2023, then surged by 79.2% to $6.9 million in 2024, then skyrocketed by 55.84% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Shares Outstanding (Diluted Average) are $10.7 million (Q3 2025), $11.0 million (Q2 2025), and $6.9 million (Q4 2024).